# Pizarra — PT-pseudo_132e0000c0e0 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_132e0000c0e0
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 13.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 0.52 ng/mL/yr
  - Prior PSA: 13.3 ng/mL
  - Prostate volume: 68.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83881855 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Chronic kidney disease
  - Problem list / PMHx: Chronic kidney disease
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 13.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 68 mL. csPCa 0.84.

Vitals: weight 91 kg, height 179 cm, BMI 28.4, BP 107/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2010).

Chief complaint: A clinical review was requested after a previous negative biopsy and a subsequent rise in PSA levels to 13.6 ng/mL.

History: At 57 years of age, this retired greenhouse horticulturalist is married and living with his partner. Adult children visit weekly. Clinical investigation began in late 2023 due to an upward PSA trajectory. Current symptom burden includes moderate lower urinary tract complaints, registering an IPSS score of 12. Nocturia occurs twice per night, accompanied by a somewhat diminished stream, yet hematuria and pelvic discomfort are absent. Chronic kidney disease defines his medical background, currently showing an eGFR below 60 mL/min/1.73m². He maintains a daily twenty-minute walking regimen and abstains from alcohol entirely. Smoking cessation occurred in 2010, concluding a thirty-five pack-year habit. Outside urological concerns, vascular surgery addressed symptomatic varicose veins recently, while dermatology treated actinic keratoses the previous month. His residence sits more than ninety minutes from the hospital, leading him to favor telephone updates when feasible, with his sister listed as next of kin.

Physical examination: DRE: Normal examination. The prostate presents as symmetrically enlarged yet benign, characterized by a smooth, firm consistency without palpable nodules or asymmetry. Vital parameters remain stable, recording a blood pressure of 107/77 mmHg and a heart rate of 64 bpm. General inspection reveals no pallor, jaundice, or peripheral lymphadenopathy.

Patient info: retired greenhouse horticulturalist; Married; Lives with partner; adult children visit weekly.
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Vascular surgery — varicose veins consult; Dermatology — actinic keratosis check.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.74 +/- 0.13   (95% CI 0.49-0.99)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.82 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence that changes the decision regarding biopsy?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on the mpMRI findings and the history of prior negative biopsy, as the statistical prior and protocol criterion are inconclusive without the retrieved documents.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, missing the context of the PI-RADS 5 score, the PSA velocity (0.52 ng/mL/yr), and the patient's history of Chronic Kidney Disease (eGFR < 60 mL/min/1.73m²).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.74), but the guideline criterion suggests avoiding repeat biopsy for PI-RADS 3 or lower lesions that have not changed, which conflicts with the high PI-RADS 5 score. The high aleatoric uncertainty (H=0.82) suggests the model struggles with this specific high-risk scenario, potentially over-weighting the high PSA/PI-RADS 5 combination without fully integrating the negative prior biopsy status.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Does the PSA trend provide evidence that changes the decision regarding biopsy?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the full laboratory results, specifically PSA density, to assess against risk-adapted matrices?
GUIDELINE ANCHOR
The guideline suggests repeating biopsy depends on risk factors like PSA density and PI-RADS score.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Report Source: Spaarne Gasthuis Radiology | Date: 28 Jan 2025 | Study: Multiparametric MRI of the Prostate
The report identifies a PI-RADS 5 lesion in the right anterior mid-gland measuring approximately 14 mm. It notes no evidence of extraprostatic extension or seminal vesicle invasion.

get_psa_trend
The PSA trend shows a rising trajectory: 4.4 ng/mL (Dec 2023) to 13.6 ng/mL (Feb 2025).

get_previous_notes
The previous note confirms a systematic transrectal ultrasound-guided biopsy in July 2023 which was negative (benign), leading to no urological referral at that time.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents that would necessitate opening it.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right anterior mid-gland measuring 14 mm.
- PSA trend: Significant rising trajectory from 4.4 ng/mL in Dec 2023 to 13.6 ng/mL in Feb 2025.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative (benign) in July 2023.

WHERE THIS LEANS
The high-risk PI-RADS 5 finding combined with a significant PSA velocity strongly supports proceeding with a targeted biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI showing PI-RADS 5 and rising PSA trend, and prior negative biopsy) strongly support proceeding with a targeted biopsy, settling the decision for this round.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with a targeted biopsy is supported by convergence across all inputs. The PI-RADS 5 finding in the mpMRI, combined with the significant PSA velocity of 0.52 ng/mL/yr, strongly indicated re-biopsy per the guideline criterion. This finding overturned the prior negative biopsy status, which was the key factor driving the evidence toward sampling. The statistical prior also supported this direction, leading to a clear consensus.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
